p27(KIP1) is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome

British Journal of Cancer

Volumn 80, Issue 9, 1999, Pages 1427-1434

  Saez A I ^a   Sanchez E ^a   Sanchez Beato M ^a   Cruz, M A ^a   Chacon I ^a   Munoz E ^a   Camacho, F I ^a   Martinez Montero J C ^a   Mollejo, M ^a   Garcia J F ^a   Piris, M A ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

CDK inhibitors; Diffuse large B cell lymphoma; MIB1; p27(KIP1); Survival analysis

Indexed keywords

KI 67 ANTIGEN; PROTEIN P27; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; MICROTUBULE ASSOCIATED PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; LARGE CELL LYMPHOMA; METABOLISM; MORTALITY; PATHOLOGY; SURVIVAL RATE;

CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MICROTUBULE-ASSOCIATED PROTEINS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 0032589191     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690539     Document Type: Article

References (58)

1. KIP1 is associated with enhanced survival under three-dimensional growth conditions during melanoma progression. Proc Am Assoc Cancer Res 38: 496
2. KIP1 with cyclin A-CDK2 and cyclin D2-CDK4. J Biol Chem 41: 25863-25872
3. KIP1 protein: prognostic implications in primary breast cancer. Nat Med 3: 227-230
4. Chan FKM, Zhang J, Cheng L, Shapiro DN and Winoto A (1995) Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16INK4. Mol Cell Biol 15: 2682-2688
5. KIP1 regulated by mitogen-activated protein kinase (MEK1). Proc Natl Acad Sci USA 95: 1092-1096
6. KIP1 for restriction point control of the fibroblasts cell cycle. Science 2: 877-880.
7. Cox DR (1972) Regression models and life tables. J R Stat Soc (B) 34: 187-220
8. KIP1 on resistance of tumor cells to anticancer agents. Nat Med 2: 1204-1210.
9. El-Deiry WR, Tokino T, Veculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW and Vogesltein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825
10. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G and Landberg G (1998) Expression of cyclin E and the cyclin dependent kinase inhibitor p27 in malignant lymphomas: prognostic implications. Blood 92: 770-777
11. KIP1 in non-small-cell lung cancer. Cancer Res 15: 3381-3385
12. Fang F, Orend G, Watanabe N, Hunter T and Ruoslathi E (1996) Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 271: 499-502
13. KIP1 deficient mice. Cell 85: 733-744
14. KIP1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94: 6380-6385
15. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P, Coldman AJ, Reed JC and Connors JM (1997) Prognostic significance of Bcl-2 protein expression and bcl 2 gene rearrangement in diffuse aggressive non Hodgkin's lymphoma. Blood 90: 244-251
16. Grogan TM, Lippman SM, Spier CM, Slymen DJ, Rybski JA, Rangel CS, Richter LC and Miller TP (1988) Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 71: 1157-1160
17. INK4/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8: 2939-2952
18. INK4B is a potential effector of TGF-β induced cell cycle arrest. Nature 371: 257-261
19. Harper JW, Adami GY, Wei N, Keyomarsi K and Elledge SJ (1993) The p21 Cdk interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent. Cell 75: 805-816
20. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B and Gatter KC (1994) A revised European-American classification of lymphoid neoplasm: A proposal from the International Lymphoma Study Group. Blood 84: 1361-1392
21. KIP1 accumulation during the cell cycle. Science 271: 1861-1864
22. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyas F and Gaulard P, for the Groupe d'Etude des lymphomes de l'Adulte (GELA) (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 87: 265-272
23. Hill ME, MacLennan KA, Cunningham DC, Vaughan Hudson B, Burke M, Clarke P, Di Stefano F, Anderson L, Vaughan Hudson G, Mason D, Selby P and Linch DC (1996) Prognastic significance of Bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large non-Hodgkin's lymphoma: a British national lymphoma investigation study. Blood 88: 1046-1051
24. Kaplan EL and Meier P (1985) Non-parametric estimation for incomplete observations. J Am Stat Assoc 53: 457-48
25. KIP1) of cyclin-dependent kinase 4 activation. Cell 79: 487-496
26. KIP1 in human malignancies. Cancer Res 55: 2266-2269
27. KIP1. Cell 85: 721-732
28. Kramer MHH, Hermans J, Parker J, Krol AD, Kluin-Nelemans JC, Haak HL, van Groningen K, van Krieken JH, de Jong D and Kluin PM (1996) Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 14: 2131-2138
29. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9: 639-649
30. Loda M, Cukor B, Tam SW, Lavin P, Florentino M, Draetta GF, Jessup M and Pagano M (1997) Increase proteasoma-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3: 231-235
31. CIP1 in the maintenance of stem/progenitor cells in vivo. Blood 88: 3710-3710
32. Mantel N (1966) Evaluation of survival and two new rank order statistics arising in its consideration. Cancer Chemother Rep 51: 163-170
33. Martin AR, Weisenburger DD, Chan WC, Ruby EI, Anderson JR, Vose JM, Bierman PJ, Bast MA, Daley DT and Armitage JO (1995) Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 85: 3671-3678
34. KIP2, a structurally distinct member of the Cip1 CDK inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9: 650-662
35. Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nuthwani BN, Schnitzer B, Tubbs RR, Gaynor ER and Fisher RI (1994) Prognostic significance of the Ki-67-associated proliferative antigen in aggresive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group Trial. Blood 83: 1460-1466
36. KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukaemia/lymphoma. Blood 86: 1924-1930
37. KIP1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707-720
38. KIP1 cyclin-dependent kinase inhibitor prevented by rampamycin. Nature 372: 570-573
39. KIP1 gene to 12p13 and its analysis in leukemias. Cancer Res 55: 1206-1210.
40. Piris MA, Pezella F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, Cuena R, Cruz MA, Martinez B, Garrido MC, Gatter K, Aiello A, Delia D, Giardini R and Rilke F (1994) p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 69: 337-341
41. KIP1, a cylin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66
42. KIP1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222-225
43. KIP1 a cyclin-dependent kinase inhibitor. Am J Pathol. 153: 175-182
44. KIP1 co-ordinate their inhibitory interactions with CDK4 and CDK2. Genes Dev 11: 492-503
45. Sánchez E, Chacon I, Plaza MM, Muñoz E, Cruz MA, Martinez B, Lopez L, Martinez-Montero JC, Orrader JL, Saez AI, Garcia JF and Piris MA (1998) Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell cycle regulator proteins. J Clin Oncol 16: 1931-1939
46. KIP1 expression is inversely proportional to the proliferative index. Am J Pathol 151: 151-160
47. Serrano M, Hannon GJ and Reach D (1993) A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707
48. KIP1 in Human Breast Cancers, Clinical Cancer Res 3: 1879-1887
49. Shiohara M, El-Diery WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B and Koeffler HP (1994) Absence of Waf1 mutations in a variety of human malignancies. Blood 84: 3781-3784
50. Slymen DJ, Miller TP, Lippman SM, Spier CM, Kerrigan DP, Rybski JA, Rangel CS, Richter LC and Grogan TM (1990) Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. J Clin Oncol 8: 986-993
51. Soos TJ, Kiyokawa H, Yan JS, Rubin MS, Giordano A, DeBlasio A, Bottega S, Wong B, Mendelson J and Koff A (1996) Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ 7: 135-146
52. The International Non-Hodgkin's Lymphoma Prognostic Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329: 987-994
53. KIP1, a novel inhibitor of G1 cyclin-CDK protein kinase activity, is related to p21. Cell 78: 67-74
54. KIP1 in chronic B-cell lymphocytic leukemia. Blood 91: 4694-4700
55. KIP1 overexpression causes apoptoic death of mammalian cells. Oncogene 15: 2991-29978
56. Watanabe H, Fukuchi K, Takagi Y, Tomoyusu S, Tsuruoka N and Gomi K (1995) Molecular analysis of the Cip1/Waf1 (p21) gene in diverse types of human tumors. Biochim Biophys Acta 1263: 275-278
57. Yamanaka N, Harabuchi Y and Kataura A (1992) The prognostic value of Ki-67 antigen in non-Hodgkin's lymphoma of Waldeyer ring and the nasal cavity. Cancer 70: 2342-2349
58. KIP1 in human lung cancers: Differential changes in small-cell and non-small-cell carcinomas. Cancer Res 58: 1042-1047